VIGAMOX EYE DROPS 0.5% BOTTLE 5ML

Eye drops

Active ingredient

1 ml contains
Active substances: moxifloxacin hydrochloride 5.45 mg (equivalent to 5 mg moxifloxacin),
Excipients: sodium chloride, boric acid, hydrochloric acid and / or sodium hydroxide (to adjust the pH), purified water.

5 ml

Mechanism of action

VIGAMOX DROPS EYE - universal antibiotic for the prevention and treatment of bacterial infections of the eyes.
- a wide range of antibacterial action
- pronounced antimicrobial effect
- good penetration into all tissues and media of the eye
- good security profile at the system level
- special mechanisms to counter the development of resistance
- approved for use in children from 1 year

Indications and usage

Topical treatment of bacterial conjunctivitis caused by the following sensitive bacteria:
Gram positive bacteria:
Corynebacterium species
Microbacterium species
Micrococcus luteus [including Erythromycin, Gentamicin, Tetracycline and / or trimethoprim resistant strains]
Staphylococcus aureus [including meticillin, erythromycin, gentamicin, Ofloxacin, tetracycline and / or trimethoprimus resistant strains]
Staphylococcus epidermidis [including meticillin, erythromycin, gentamicin, ofloxacin, tetracycline and / or trimethoprimus resistant strains]
Staphylococcus heamolyticus [including meticillin, erythromycin, gentamycin, ofloxacin, tetracycline and / or trimethoprimus resistant strains]
Staphylococcus hominis [including meticillin, erythromycin, gentamicin, ofloxacin, tetracycline and / or trimethoprimus resistant strains]
Staphylococcus warneri [including erythromycin resistant strains]
Streptococcus mitis [including strains resistant to penicillin, erythromycin, tetracycline and / or trimethoprim]
Streptococcus pneumoniae [including strains resistant to penicillin, erythromycin, gentamicin, tetracycline and / or trimethoprimu]
Streptococcus viridans [including strains resistant to penicillin, erythromycin, tetracycline and / or trimethoprim]
Gram negative bacteria:
Acinetobacter species
Haemophilus “alconae”
Haemophilus influenzae [including ampicillin resistant strains]
Klebsiella pneumoniae [including ampicillin-resistant strains]
Moraxella catarrhalis
Pseudomonas aeruginosa
Other microorganisms:
Chlamydia trachomatis

Contraindications

Hypersensitivity to any component of the drug.
Drug interactions:
Unlike other fluoroquinolones, no clinically significant drug interactions between systemic use of moxifloxacin and intraconazole, theophylline, Warfarin, Digoxin, oral contraceptives, probenzidine, Ranitidine, or glyburide are noted. Moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9 or CYP1A2, which suggests that it most likely does not change the pharmacokinetic properties of drugs metabolized by cytochrome P450 isoenzymes.

Pregnancy and Breastfeeding

Pregnancy
Vigamox should be prescribed to pregnant women only if the expected benefit from its use greatly exceeds the potential risk to the fetus.
Lactation
Since it is not known whether moxifloxacin penetrates into breast milk, Vigamox should be prescribed with caution to nursing mothers.

Dosage and administration

Instill into the affected eye (eyes) 1 drop 3 times a day for 4 days.
Do not touch the pipette tip with your eyes or any other surface to avoid contamination of the contents of the vial.
The use of Vigamox eye drops in children and newborns is as effective and safe as when using the drug in adults and can be given in the same dose as for adult patients.

Adverse reactions

Local
- blurred vision;
- transient discomfort;
- itching;
- dry eyes;
- keratitis;
- subconjunctival bleeding.
Systemic
When absorbed in rare cases may occur:
Cardiovascular: cardiovascular collapse, vascular edema (including laryngeal, pharyngeal, or facial edema);
From the side of the central nervous system: loss of consciousness, headache;
Respiratory: respiratory failure, pharyngitis;
From the urinary-genital system: utricauria.

As in the case of other antibacterial agents, prolonged use of the drug can cause excessive growth of insensitive organisms, including fungi.When superinfection is necessary to stop taking the drug and consider alternative therapies.
Risk of anaphylactic reaction
Patients taking systemic quinolone drugs may have a history of severe Anaphylactic reactions. If an allergic reaction develops during the use of moxifloxacin, it is necessary to stop taking the drug. Severe acute hypersensitivity to moxifloxacin or any other component of the drug may require emergency therapy. According to clinical indications, they use oxygen and conduct artificial respiration.

Overdosage

The limited capacity of the conjunctival bag makes it impossible to overdose with the ophthalmic drug Vigamox.
Also excluded intoxication after accidental ingestion.

Storage conditions

Store at temperatures from +20 to + 250C.
 

2.5 years

Vigamox ophthalmic